Although the overall performance of healthcare stocks has recently failed to outperform the broader market, this does not mean the sector lacks investment value. For investors with a long-term perspective, willing to hold for five years or more, many healthcare companies present attractive potential. Among them, innovative biopharmaceutical companies CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) merit close attention.
Gene editing expert CRISPR Therapeutics is poised to encounter several positive catalysts by 2026. The primary focus lies in its partnered gene therapy Casgevy, developed with Vertex, for treating sickle cell disease and beta-thalassemia. Although it has not yet generated significant revenue due to complex approval processes, the company expects substantial growth next year. This is attributed to efforts over the past two years to expand third-party payer coverage and establish a network of authorized treatment centers. Additionally, late-stage clinical trials for patients aged 5 to 11 are underway, with the potential to broaden the eligible patient population.
Beyond Casgevy, the company’s research and development pipeline is full of potential. Although, as a small biotech firm, it always faces clinical and regulatory risks, CRISPR Therapeutics demonstrates innovative capabilities in treatment areas awaiting breakthroughs, providing possibilities for its long-term development. If it can replicate Casgevy’s success in more areas, the company’s stock price has room for upward movement in the medium to long term.
Although Vertex Pharmaceuticals has faced recent stock price pressure, with market concerns over its reliance on its cystic fibrosis product line, this core business continues to provide the company with stable and robust financial support. In the third quarter, the company’s revenue increased by 11% year-over-year to $3.08 billion, while net earnings per share grew by 4.7% year-over-year to $4.20. Furthermore, no significant competitive threats have emerged in the segment it has dominated for over a decade.
The company has ample time to drive the adoption of new products. In addition to Casgevy, developed in partnership with CRISPR, another therapy, Journavx, approved this January for treating acute pain, is yet to realize its commercial potential. Looking ahead, Vertex has made significant progress in diversifying its pipeline. Therefore, temporary market performance should not obscure its solid medium-term prospects—Vertex not only maintains dominance in its core area but has also achieved substantial progress in research, development, and regulatory approvals in new therapeutic fields.
In summary, for long-term investors, CRISPR Therapeutics and Vertex Pharmaceuticals represent two different innovative paths and value propositions within the healthcare sector. The former pioneers new therapeutic frontiers with cutting-edge gene editing technology, while the latter continuously expands its product boundaries on the foundation of stable cash flow. What they share is differentiated core technology, clear R&D pipeline progression plans, and the potential to address unmet medical needs. When evaluating their investment value, it is essential to fully understand the research and development risks and long-term nature of the biopharmaceutical industry, focusing on the technological and commercial milestones these companies may achieve in the coming years.
